Holen Sie sich die Stockscreener-App
176.72
0.77%
-1.36
Schlusskurs vom Vortag:
$178.08
Offen:
$180.5
24-Stunden-Volumen:
119.33K
Relative Volume:
0.18
Marktkapitalisierung:
$9.72B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
22.06
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-5.96%
1M Leistung:
-7.22%
6M Leistung:
-18.29%
1J Leistung:
-16.45%
1-Tages-Spanne:
$175.76
$182.25
1-Wochen-Bereich:
$175.61
$190.68
52-Wochen-Spanne:
$175.61
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
176.81 | 9.72B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
561.02 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
240.65 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
145.50 | 40.96B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
198.72 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
429.11 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Labs stock target cut, hold rating on expected decline - Investing.com
Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year LowHere's Why - MarketBeat
Citi flags revenue and margin headwinds for Charles River Labs shares By Investing.com - Investing.com South Africa
Charles River Seeks Strategic Acquisitions - Marketscreener.com
Charles River Laboratories International's (CRL) "Outperform" Rating Reiterated at William Blair - MarketBeat
BofA keeps Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Canada
TD Cowen cautious on Charles River Labs stock as 2025 guide signals further declines - Investing.com India
JPMorgan maintains Charles River Labs stock at Neutral on challenges - Investing.com India
Citi flags revenue and margin headwinds for Charles River Labs shares - Investing.com India
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
Charles River Labs stock hits 52-week low at $176.34 By Investing.com - Investing.com Canada
JPMorgan maintains Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Nigeria
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
Charles River Laboratories (CRL) Provides Preliminary 2025 Finan - GuruFocus.com
Charles River Labs stock hits 52-week low at $176.34 - Investing.com India
Charles River stock falls on 2025 revenue drop (CRL:NYSE) - Seeking Alpha
Charles River Labs Discusses 2025 Financial Outlook - TipRanks
Charles River Laboratories stock falls on weak 2025 revenue outlook By Investing.com - Investing.com UK
Bioanalytical Testing Services Market Size, Embracing Growth - openPR
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Reinhart Partners LLC. Sells 11,822 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference - sharewise
Charles River Labs to Present Strategic Overview at J.P. Morgan Healthcare Conference - StockTitan
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
First Hawaiian Bank Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You - Simply Wall St
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Deciphex Secures $32.3M Series C to Transform AI-Powered Pathology Diagnosis - StockTitan
Preclinical Medical Device Testing Services Market Outlook, - GlobeNewswire
Preclinical Medical Device Testing Services Market Outlook, 2025-2035Dominated by Charles River Laboratories Int'l, Eurofins Scientific, SGS, WuXi AppTec, and Pace Analytical Services - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Should You Retain Charles River Stock in Your Portfolio Now? - MSN
CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag - AccessWire
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? - MSN
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Zacks Research Issues Negative Forecast for CRL Earnings - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)? - Simply Wall St
RNA Therapy Clinical Trials Market Top Companies StudyIQVIA; - openPR
Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market - MarketWatch
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For August 2025 - Nasdaq
Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Average Price Target from Brokerages - MarketBeat
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
Sanctuary Advisors LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Lord Abbett & CO. LLC Acquires 5,959 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):